Scripps Whittier Diabetes Institute
La Jolla, California, 92037, United States
NCT Number: NCT03068273
This program will provide patients with type 1 and high risk type 2 diabetes the safest hospitalization by using wireless continuous glucose monitoring devices (CGM) to track their glucose parameters in real-time similar to other continuously monitored vital signs. The CGM will inform a team of health professionals who will monitor the patients' progress, communicate recommendations, and be available for discussion when recommended targets are not achieved. Health teams will utilize sensor results in addition to existing electronic medical records data to evaluate progress and manage care.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
La Jolla, California, 92037, United States
All patients with type 1 or type 2 diabetes who meet study criteria will be invited to participate in the study. All patients included in the study will be followed by an advanced practice diabetes nurse for glucose management during their hospitalization. All patients included in the study will receive a CGM. Patients with type 2 diabetes will be randomized to control (blinded CGM glucose values to APN, care team and researchers) or intervention (CGM blood glucose values will be used to aid with glucose management during the hospitalization). In addition, a research only supplemental order set will be implemented for all study participants. The order set focuses on any glucose point of care test that is between 70-79 mg/dL or ≥ 250 at bedtime or before the 4 am usual care blood glucose check. The goal is to prevent hypoglycemia and hyperglycemia for all study patients. The advanced practice diabetes nurse will work with the physician in charge of the patient's care as well as the patient's care team.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
(not all listed):
Time frame: Up to 30 days
Percentage of time a person's blood glucose level stays within a specific range of 70-180 mg/dL
Time frame: Up to 30 days
Percentage of time a person's blood glucose level stays within a specific range on 70-200 mg/dL
Time frame: Up to 30 days
Percentage of time a person's blood glucose level stays within a specific range on 70-250 mg/dL
Time frame: Up to 30 days
Percentage of time a person's blood glucose level stays within a specific range < 70 mg/dL
Time frame: Up to 30 days
Percentage of time a person's blood glucose level stays within a specific range > 250 mg/dL
Scripps Whittier Diabetes Institute
Other
Acronym: CGM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06890208
Anxiety Disorders, Arrhythmias, Cardiac
Hamburg, Germany
View Trial DetailsNCT07052292
Autoimmune Diseases, Diabetes Mellitus
Wroclaw, Kuyavian-Pomeranian Voivodeship, Poland
View Trial DetailsNCT03987802
Autoimmune Diseases, Diabetes Mellitus
Hyderabad, Andhra Pradesh, India
View Trial DetailsNCT06330194
Autoimmune Diseases, Chronic Disease
Copenhagen, Denmark
View Trial Details